Mylan announced the launch of Epinephrine Injection Auto-Injector, the authorized generic for EpiPen Auto-Injector. The generic 2-pack auto-injectors will be offered at >50% lower than the wholesale acquisition cost (WAC) of the brand EpiPen Auto-Injector.
Epinephrine Injection, a non-selective alpha and beta-adrenergic receptor agonist, is indicated for the emergency treatment of allergic reactions (Type I) including anaphylaxis. Epinephrine lessens the vasodilation and increased vascular permeability that occurs during anaphylaxis and causes bronchial smooth muscle relaxation and helps alleviate bronchospasm. It also relieves pruritus, urticaria, and angioedema, and may relieve gastrointestinal and genitourinary symptoms associated with anaphylaxis.
Additional patient purchase options for the 2-pack auto-injectors will be available as well as a savings card for eligible patients with commercial health insurance. For the uninsured and underinsured, Mylan will continue to offer its patient assistance program.
Mylan’s authorized generic version will be available in 0.15mg and 0.3mg strengths. It is anticipated to be available in pharmacies starting next week.